

4th Think Tank
on Advancing
Gastroesophageal
Cancer Research
November 12, 2020

MEETING PROGRAM

PRESENTED BY
Adam Bass, MD & TargetCancer Foundation



TargetCancer
Foundation



4th Think Tank
on Advancing
Gastroesophageal
Cancer Research
November 12, 2020

Thank you for joining the 2020 Think Tank on Advancing Gastroesophageal Cancer Research. We are sorry that we can't meet in person, but we are excited to present the Think Tank virtually and welcome a large international community this year. While we can not replicate the in-person conversations and networking that make the Think Tank so valuable, we hope that the presentations today will still lead to new collaborations, define research priorities for the field, and ultimately accelerate the identification of new treatments.

Our sincere thanks to our partners who worked with us to plan this meeting and its conversion to a virtual format over the past year: Drs. Julian Abrams, Jim Goldenring, Sam Klempner, Monika Laszkowska, and Matthew Stachler.

We hope that you enjoy today's program, and look forward to gathering again in person soon.

Jim Palma
TargetCancer Foundation

Adam Bass, MD
Dana-Farber Cancer Institute

AGENDA

THURSDAY, NOVEMBER 12, 2020

8:45-8:55a WELCOME & INTRODUCTIONS

9:00-10:25a MAIN SESSION

Clonal transitions and phenotypic evolution in Barrett's Esophagus

Stuart McDonald, PhD, *Barts Cancer Institute*

Multimodal tethered capsule endomicroscopy for improved diagnosis of Barrett's Esophagus

Andreas Wartak, PhD, *Massachusetts General Hospital and Harvard Medical School*

Modeling Esophageal Adenocarcinoma in the mouse model

Michael Quante, MD, *University of Freiburg*

10:25-10:35a STRETCH & BYO COFFEE

10:35-11:20a RAPID-FIRE ABSTRACT PRESENTATIONS

Pre-existing tumor-infiltrating T cells influence response to neoadjuvant chemotherapy in Esophageal Adenocarcinoma

Ruben Goedegebuure, MD, *Amsterdam UMC*

Proanthocyanidins enhance chemotherapy induced Esophageal Adenocarcinoma cell death

Laura Kresty, MS, PhD, *University of Michigan*

Increased HNF4A dosage regulates CDX2 expression in intestinal metaplasia via binding a novel unguarded enhancer

Harshabad Singh, MBBS, *Dana-Farber Cancer Institute*

11:25-12:15p MAIN SESSION CONTINUED

Oral health and risk of upper gastrointestinal cancers in a large prospective study from a high-risk region: Golestan Cohort Study

Yukiko Yano, PhD, *National Cancer Institute*

Chronic inflammation and cancer

Thea Tlsty, PhD, *University of California, San Francisco*

12:20-12:30p CLOSING REMARKS

SPEAKERS



STUART MCDONALD, MD
BARTS CANCER INSTITUTE

Twitter: [@mcdona02](#)

<https://www.bartscancer.london/staff/dr-stuart-mcdonald/>



MICHAEL QUANTE, PhD
UNIVERSITY OF FREIBURG

Twitter: [@QuanteMichael](#)

<https://www.quantelab.org/people.html>



THEA TLSTY, PhD
UNIVERSITY OF CALIFORNIA, SAN FRANCISCO

http://cancer.ucsf.edu/people/profiles/tlsty_thea.3688



TOP-TIER ABSTRACTS

Andreas Wartak, PhD

Massachusetts General Hospital, Harvard Medical School

Multimodal tethered capsule endomicroscopy for improved diagnosis of Barrett's Esophagus

Yukiko Yano, PhD

National Cancer Institute

Oral health and risk of upper gastrointestinal cancers in a large prospective study from a high-risk region: Golestan Cohort Study

RAPID-FIRE ABSTRACTS

Laura Kresty, MS, PhD

University of Michigan

Proanthocyanidins enhance chemotherapy induced Esophageal Adenocarcinoma cell death

Ruben Goedegebuure, MD

Amsterdam UMC

Pre-existing tumor-infiltrating T cells influence response to neoadjuvant chemotherapy in esophageal adenocarcinoma

Harshabad Singh, MBBS

Dana-Farber Cancer Institute

Increased HNF4A dosage regulates CDX2 expression in intestinal metaplasia via binding a novel un-guarded enhancer

TRACK

TARGET → RARE → CANCER → KNOWLEDGE

Driving precision medicine in rare cancers.

TCF-001 TRACK is a prospective clinical study (NCT04504604) seeking to enroll 400 patients with rare cancers or cancer of unknown primary.

TRACK was developed by TargetCancer Foundation in collaboration with academic investigators and in partnership with Foundation Medicine.

TCF-001 TRACK Goals and Objectives:

- Perform comprehensive genomic profiling of tissue and blood (FoundationOne CDx & FoundationOne Liquid CDx) at no cost to patients.
- Convene an expert Virtual Molecular Tumor Board (VMTB) to provide recommendations for on-label, off-label, or clinical trial treatments.
- Utilize remote consenting to allow patients to enroll from their homes, eliminating travel requirements and expanding study geographic reach.
- Track patient outcomes for a minimum of one year, repeating FoundationOne Liquid CDx 2-3 times and providing additional VMTB recommendations based on discovery of new actionable alterations.
- Characterize the genomic landscape of rare cancers.

To learn more about TCF-001 TRACK, contact Jim Palma at jim@targetcancerfoundation.org, or visit targetcancerfoundation.org/track.




TargetCancer
Foundation

Through multiple efforts, TargetCancer Foundation is driving the gastroesophageal cancer research field forward:

- A seven-year commitment to funding innovative and impactful esophageal cancer research at the Bass Lab at the Dana-Farber Cancer Institute, focusing on genomic studies and the role of immunotherapy.
- Support for studies around a key immunotherapy clinical trial, which has led to an improved treatment opportunity for esophageal cancer patients.
- Hosting the annual Think Tank on Advancing Gastroesophageal Cancer Research, a unique scientific meeting that fosters collaboration and idea generation among leading clinicians, researchers, advocates and patients.
- Partnering with Count Me In at the Broad Institute of MIT and Harvard on the development of the **Esophageal and Stomach Cancer Project**, an initiative that partners with patients to generate critical research data. Learn more at: www.escproject.org.

TargetCancer Foundation also drives other rare cancer programs:

- Developing innovative rare cancer studies, such as TCF-001 TRACK, which impact patients directly while simultaneously generating critical research data.
- Providing over ten years of funding for innovative, high-impact cholangiocarcinoma research focusing on the development of cell lines, mouse models, and genomic studies.
- Lowering barriers to clinical trials through direct patient guidance and comprehensive genomic profiling awareness and access programs.
- Serving as a public voice to raise awareness of the challenges faced by the rare cancer patient and research community, and leading a nationwide coalition of advocacy foundations devoted to rare cancers.



TargetCancer Foundation promotes the development of lifesaving treatment protocols for rare cancers. TargetCancer Foundation directly supports initiatives at the forefront of cancer treatment by funding innovative research, fostering collaborations, and raising awareness among scientists, clinicians, and patients.



TargetCancer Foundation

For more information, visit
www.targetcancerfoundation.org

One Broadway, 14th Floor
Cambridge, MA 02142
info@targetcancerfoundation.org
617-765-4881

